The phase Ib KEYNOTE-028 study enrolled patients with PD-L1 ≥1% of tumor or stromal cells and patients received pembrolizumab 10 mg/kg every two weeks until disease progression or intolerable toxicity for up to 24 months [99]. This evidence concerns the gene CD274 and neoplasm.